Lacosamide Pregnancy and Breastfeeding Warnings

Lacosamide is also known as: Vimpat

Lacosamide Pregnancy Warnings

UCB, Inc. has established the UCB AED Pregnancy Registry to advance scientific knowledge about safety and outcomes in pregnant women being treated with lacosamide. To ensure broad program access and reach, either a healthcare provider or the patient can initiate enrolment in the UCB AED Pregnancy Registry by calling 1-888-537-7734. Physicians are also advised to recommend that pregnant patients taking lacosamide enroll in the North American Antiepileptic Drug Pregnancy Registry. This can be done by calling 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at

Lacosamide has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of increased embryofetal mortality, perinatal mortality, and growth deficit. There are no controlled data in human pregnancy. Lacosamide should only be given during pregnancy when benefits outweigh risks.

Lacosamide Breastfeeding Warnings

There are no data on the excretion of lacosamide into human milk. Because many drugs are excreted into human milk, a decision should be made whether to discontinue nursing or to discontinue lacosamide, taking into account the importance of the drug to the mother.

Animal studies have reported that lacosamide and/or its metabolites are excreted into milk.

See Also...
